A prognostic test to guide adjuvant chemotherapy (ACT) decisions in early-stage non-small cell lung cancer (NSCLC): A cost-effectiveness analysis.

被引：0
|
作者：
Stenehjem, David D.
Bellows, Brandon Kyle
Kaldate, Rajesh R.
Jones, Joshua Timothy
Siebert, Uwe
Brixner, Diana I.
机构：
[1] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA
[2] Univ Utah, Pharmacotherapy Outcomes Res Ctr, Salt Lake City, UT USA
[3] Myriad Genet Labs Inc, Salt Lake City, UT USA
[4] Myriad Genet Inc, Salt Lake City, UT USA
[5] Univ Hlth Sci Med Informat & Technol, Hall In Tirol, Austria
[6] Univ Utah, LS Skaggs Pharm Inst, Salt Lake City, UT USA
[7] Univ Utah, Program Personalized Hlth Care, Salt Lake City, UT USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.e18509
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e18509
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Cost-Effectiveness of a 14-Gene Risk Score Assay to Target Adjuvant Chemotherapy in Early Stage Non-Squamous Non-Small Cell Lung Cancer
    Roth, Joshua A.
    Billings, Paul
    Ramsey, Scott D.
    Dumanois, Robert
    Carlson, Josh J.
    ONCOLOGIST, 2014, 19 (05): : 466 - 476
  • [42] Patient and clinician perspectives on adjuvant treatment in early-stage non-small cell lung cancer (NSCLC): Qualitative results
    Collacott, H.
    Okhuoya, P.
    Sandelin, M.
    Michaels-Igbokwe, C.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S100 - S100
  • [43] Neo-adjuvant chemotherapy in early stage non-small cell lung cancer
    Boukovinas, Ioannis
    Tsakiridis, Kosmas
    Zarogoulidis, Paul
    Machairiotis, Nikolaos
    Katsikogiannis, Nikolaos
    Kougioumtzi, Ioanna
    Zarogoulidis, Kostantinos
    JOURNAL OF THORACIC DISEASE, 2013, 5 : S446 - S448
  • [44] A COST-EFFECTIVENESS ANALYSIS OF ATEZOLIZUMAB AS ADJUVANT TREATMENT FOLLOWING COMPLETE RESECTION AND PLATINUM-BASED CHEMOTHERAPY IN ADULT PATIENTS WITH EARLY-STAGE NON-SMALL CELL LUNG CANCER WITH A HIGH RISK OF RECURRENCE
    Miguel, Silva L.
    Pinheiro, B.
    Carvalho, P.
    Jovanoski, N.
    Belleli, R.
    Abogunrin, S.
    Alves, P.
    Araujo, A.
    Barata, F.
    Hespanhol, V
    da Luz, R.
    Borges, M.
    VALUE IN HEALTH, 2023, 26 (12) : S65 - S65
  • [45] Thermal ablation versus stereotactic body radiotherapy for stage I non-small cell lung cancer: A cost-effectiveness analysis.
    Wu, Xiao
    Uhlig, Johannes
    Blasberg, Justin
    Gettinger, Scott N.
    Suh, Robert
    Solomon, Stephen Barnett
    Kim, Kevin
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [46] BUDGET IMPACT OF THE 14-GENE RISK-SCORE (RS) ASSAY TO INFORM ADJUVANT CHEMOTHERAPY DECISIONS IN EARLY-STAGE NON-SMALL CELL LUNG CANCER (NSCLC)
    Roth, J. A.
    Billings, P.
    Ramsey, S.
    Dumanois, R.
    Carlson, J. J.
    VALUE IN HEALTH, 2014, 17 (03) : A74 - A74
  • [47] Patients' confidence in treatment decisions for early stage non-small cell lung cancer (NSCLC)
    Pompili, Cecilia
    Holch, Patricia
    Rogers, Zoe
    Absolom, Kate
    Clayton, Beverly
    Franks, Kevin
    Bekker, Hilary
    Velikova, Galina
    HEALTH AND QUALITY OF LIFE OUTCOMES, 2020, 18 (01)
  • [48] Patients’ confidence in treatment decisions for early stage non-small cell lung cancer (NSCLC)
    Cecilia Pompili
    Patricia Holch
    Zoe Rogers
    Kate Absolom
    Beverly Clayton
    Kevin Franks
    Hilary Bekker
    Galina Velikova
    Health and Quality of Life Outcomes, 18
  • [49] Role of chemotherapy and targeted therapy in early-stage non-small cell lung cancer
    Nagasaka, Misako
    Gadgeel, Shirish M.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2018, 18 (01) : 63 - 70
  • [50] COST-EFFECTIVENESS OF THE SECOND LINE TREATMENT FOR ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Chang, C. W.
    Lang, H. C.
    VALUE IN HEALTH, 2019, 22 : S165 - S166
12345